Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ropidoxuridine by Shuttle Pharmaceuticals for Sarcomas: Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
Ropidoxuridine by Shuttle Pharmaceuticals for Small Intestine Cancer: Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Small Intestine Cancer. According to GlobalData,...
Ropidoxuridine by Shuttle Pharmaceuticals for Gastric Cancer: Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
Ropidoxuridine by Shuttle Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
Ropidoxuridine by Shuttle Pharmaceuticals for Colon Cancer: Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Colon Cancer. According to GlobalData, Phase...
Ropidoxuridine by Shuttle Pharmaceuticals for Rectal Cancer: Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Rectal Cancer. According to GlobalData, Phase...
Ropidoxuridine by Shuttle Pharmaceuticals for Liver Cancer: Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Liver Cancer. According to GlobalData, Phase...
Ropidoxuridine by Shuttle Pharmaceuticals for Esophageal Cancer: Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
Ropidoxuridine by Shuttle Pharmaceuticals for Glioblastoma Multiforme (GBM): Likelihood of Approval
Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...